Swatilekha Ghosh
Overview
Explore the profile of Swatilekha Ghosh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattacharjee M, Ghosh A, Das S, Sarker S, Bhattacharya S, Das A, et al.
ACS Biomater Sci Eng
. 2024 Sep;
10(10):6314-6331.
PMID: 39285678
Multi drug resistance (MDR) in breast carcinoma still poses a significant impairment to successful chemotherapy. As the arsenal of anticancer agents increases with improved preclinical methods, the growth of therapeutic...
2.
Bhattacharya S, Sarker S, Das S, Ahir M, Chattopadhyay S, Ghosh S, et al.
Apoptosis
. 2023 Nov;
29(1-2):191-209.
PMID: 37945815
During cancer cell invasion, integrin undergoes constant endo/exocytic trafficking. It has been found that the recycling ability of integrin β1 through Rab11-controlled long loop pathways is directly associated with cancer...
3.
Das S, Ghosh A, Upadhyay P, Sarker S, Bhattacharjee M, Gupta P, et al.
Fitoterapia
. 2023 Jul;
169:105601.
PMID: 37406886
Cancer continues to threat mortal alongside scientific community with burgeoning grasp. Most efforts directed to tame Cancer such as radiotherapy or chemotherapy, all came at a cost of severe side...
4.
Patra A, Adhikary A, Ghosh S
Apoptosis
. 2022 Dec;
28(3-4):263-276.
PMID: 36536258
Tumor cells always have the need to produce an increased amount of proteins in the cells. This elevated amount of proteins increases the pressure on the organelles of the cell...
5.
Upadhyay P, Ghosh A, Basu A, Pranati P, Gupta P, Das S, et al.
Biomater Sci
. 2021 Nov;
9(24):8285-8312.
PMID: 34766965
Epidermal growth factor receptor (EGFR) normally over-expresses in non-small cell lung cancer (NSCLC) cells. Its mutations act as oncogenic drivers in the cellular signal transduction pathway, and induce the downstream...
6.
Ghosh A, Upadhyay P, Sarker S, Das S, Bhattacharjee M, Bhattacharya S, et al.
Biomater Sci
. 2021 Jul;
9(16):5665-5690.
PMID: 34259681
To date, most of the accessible therapeutic options are virtually non-responsive towards triple-negative breast cancer (TNBC) due to its highly aggressive and metastatic nature. Interestingly, chemotherapy reacts soundly in many...
7.
Bhattacharjee M, Upadhyay P, Sarker S, Basu A, Das S, Ghosh A, et al.
Biochim Biophys Acta Gen Subj
. 2020 Aug;
1864(11):129695.
PMID: 32735937
Background: Breast cancer intimidates the contemporary medical advances, attempting to revolutionize cancer therapeutics. While patients suffering an advanced breast cancer are dependent on mono drugs, yet the build out of...
8.
Ahir M, Upadhyay P, Ghosh A, Sarker S, Bhattacharya S, Gupta P, et al.
Biomater Sci
. 2020 Apr;
8(10):2939-2954.
PMID: 32319481
The development of new therapeutic strategies to target triple-negative breast cancer (TNBC) is in much demand to overcome the roadblocks associated with the existing treatment procedures. In this regard, therapies...
9.
Bhattacharya S, Ghosh A, Maiti S, Ahir M, Debnath G, Gupta P, et al.
J Control Release
. 2020 Apr;
322:357-374.
PMID: 32243981
Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic subtype of breast cancer showing non-responsiveness to most available therapeutic options. Therefore, smart therapeutic approaches to selectively transport and target...
10.
Upadhyay P, Sarker S, Ghosh A, Gupta P, Das S, Ahir M, et al.
Biomater Sci
. 2019 Aug;
7(10):4325-4344.
PMID: 31411213
Non-small cell lung carcinoma (NSCLC) is a highly lethal type of cancer with limited therapeutic avenues available to date. In the present study, we formulated PEGylated PLGA thymoquinone nanoparticles (TQ-Np)...